Related Experiment Video

Updated: Jun 2, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Single nucleotide polymorphisms of Toll-like receptor 4 decrease the risk of development of hepatocellular carcinoma

Shi Minmin1, Xu Xiaoqian, Chen Hao

  • 1Research Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.

Plos One
|May 12, 2011
PubMed
Abstract

Insights

Specific Toll-like receptor 4 (TLR4) gene variations, or single nucleotide polymorphisms, are linked to a reduced risk of developing hepatocellular carcinoma. These TLR4 sequence variations may offer a protective effect against liver cancer development.

Area of Science:

  • Immunology
  • Genetics
  • Oncology

Background:

  • Toll-like receptor 4 (TLR4) is a critical innate immune receptor involved in initiating inflammatory responses.
  • Genetic variations in the TLR4 gene are increasingly implicated in cancer development.
  • Hepatocellular carcinoma (HCC) is a major global health concern where genetic predisposition is a significant factor.

Purpose of the Study:

  • To investigate the association between Toll-like receptor 4 (TLR4) single nucleotide polymorphisms (SNPs) and the risk of developing hepatocellular carcinoma (HCC).
  • To determine the temporal relationship between TLR4 genetic variations and HCC development.
  • To evaluate the potential protective role of TLR4 SNPs in HCC pathogenesis.

Main Methods:

  • A case-control study was conducted involving 216 HCC cases and 228 controls.
  • Systematic genetic analysis of ten single nucleotide polymorphisms (SNPs) within the TLR4 gene sequence.
  • Evaluation of sequence variants in the 5'-untranslated region and introns of the TLR4 gene.

Main Results:

  • Six specific TLR4 SNPs (rs10759930, rs2737190, rs10116253, rs1927914, rs12377632, rs1927911) were significantly associated with a decreased risk of HCC.
  • Individuals with heterozygous genotypes for these SNPs showed a reduced risk (OR 0.527-0.578, P<0.01).
  • Haplotype analysis identified a specific TLR4 haplotype (GCCCTTAG) significantly associated with a lower occurrence of HCC (OR 0.556, 95% CI 0.407-0.758, P=0.000).

Conclusions:

  • TLR4 sequence variations are significantly associated with the risk of developing hepatocellular carcinoma.
  • Certain TLR4 single nucleotide polymorphisms demonstrate a protective role against HCC development.
  • Genetic variations in TLR4 may be a key factor in modulating susceptibility to liver cancer.

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...